TCGA-GM-A2D9-01A-11R-A18M-07
— · B
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- B
- subtype
- B
- overall_survival_months
- 60
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYOGENESIS+0.280
- PANCREAS_BETA_CELLS+0.260
- KRAS_SIGNALING_DN+0.230
- COAGULATION+0.200
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.170
- INTERFERON_ALPHA_RESPONSE+0.140
- ANGIOGENESIS+0.130
- OXIDATIVE_PHOSPHORYLATION+0.130
- P53_PATHWAY+0.080
- FATTY_ACID_METABOLISM+0.070
Top 10 suppressed
- E2F_TARGETS-0.630
- G2M_CHECKPOINT-0.560
- MITOTIC_SPINDLE-0.510
- MTORC1_SIGNALING-0.430
- MYC_TARGETS_V2-0.360
- UNFOLDED_PROTEIN_RESPONSE-0.360
- MYC_TARGETS_V1-0.320
- IL6_JAK_STAT3_SIGNALING-0.280
- SPERMATOGENESIS-0.270
- PI3K_AKT_MTOR_SIGNALING-0.260
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-GM-A5PX-01A-12R-A28M-07 | — | A | 0.868 |
| 2 | MNG25 | — | — | 0.854 |
| 3 | TCGA-49-4510-01A-01R-1206-07 | — | cohortA2 | 0.827 |
| 4 | TCGA-AO-A126-01A-11R-A10J-07 | — | A | 0.826 |
| 5 | TCGA-L9-A443-01A-12R-A24H-07 | — | cohortA1 | 0.824 |
| 6 | SRR1403222 | GTEX | — | 0.812 |
| 7 | TCGA-GM-A3NY-01A-11R-A21T-07 | — | B | 0.807 |
| 8 | SRR1380680 | GTEX | — | 0.802 |
| 9 | TCGA-62-A46P-01A-11R-A24H-07 | — | cohortA3 | 0.794 |
| 10 | TCGA-4P-AA8J-01A-11R-A39I-07 | — | — | 0.789 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 16 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYOGENESIS | 0.280 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.260 | Cobimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.230 | Remibrutinib | — uncovered |
| COAGULATION | 0.200 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.170 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.140 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.130 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.130 | Remibrutinib | — uncovered |
| P53_PATHWAY | 0.080 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.060 | Inavolisib | — uncovered |
| APOPTOSIS | 0.050 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.020 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.010 | Inavolisib | — uncovered |